Noninvasive Prenatal Testing Market Revenue to close at USD 5673.53 million by 2027
Posted On September 01, 2021
The Global Noninvasive Prenatal Testing Market is foreseen to grow at a remarkable CAGR of 10.9% during the year 2021-2027 as estimated by the report from Value Market Research wherein the market value is expected to grow to USD 5673.53 million by 2027. The key factors attributed to the growth of global noninvasive prenatal testing market during the forecast period are increasing incidence of chromosomal abnormalities with advancing maternal age and increasing occurrence of chromosomal aneuploidy in fetus. In the last 30 years, number of women conceiving at the age of 35 or above has shot up drastically leading to high risk of various chromosomal abnormalities. This has accelerated the demand for prenatal genetic counseling influencing the NIPT market. Growing preference for NIPT over invasive prenatal testing for determining the risk of chromosomal abnormalities while avoiding the risk of miscarriage will propel its market growth. Key market players emphasizing on developing advanced noninvasive prenatal screening for detecting genetic disorders at an early stage in babies will also contribute to the growth of NIPT market. Furthermore, growing awareness among people about the benefits of NIPT and various companies and laboratories signing up distribution agreements with NIPT providers will positively impact the market. However, there are some factors that may restrain noninvasive prenatal testing market growth during the forecast period. These factors include high cost and lack of adequate reimbursement limiting its uptake in developing regions. In addition, lower per capita spending on healthcare and lack of skilled professionals may also limit its market growth.
Noninvasive prenatal testing (NIPT), also known as noninvasive prenatal screening (NIPS), is a method that helps to determine if the baby is at risk of being born with certain genetic disorders such as Down syndrome, Edwards syndrome, Patau syndrome and Turner syndrome. The test analyzes the DNA, which passes into the bloodstream of the mother from the fetus during pregnancy, containing the genetic information. It is generally suggested for women who are above 35 years of age. A single blood test is required for NIPT and it can be done in the first or second trimester of pregnancy or any time once a woman is in her 10th week of pregnancy. The test is conducted using advanced DNA technology.
The geographical and segmentation study covered in the report "Global Noninvasive Prenatal Testing Market Report By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Risk Type (High & Average Risk, Low Risk), By Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA In Maternal Plasma Tests), By Technology (NGS, Array Technology, PCR, Other Technologies), By Product (Consumables & Reagents, Instruments), By End-User (Hospitals & Clinics, Diagnostic Laboratories) And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2021-2027" helps in understanding the upcoming trends of the market.
On the basis of gestation period the market is segmented into 0-12 Weeks, 13-24 Weeks, 25-36 Weeks. By risk type the noninvasive prenatal testing market is categorised as High & Average Risk, Low Risk. By method the noninvasive prenatal testing market is categorised as Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests. Based on technology the noninvasive prenatal testing market is segmented as NGS, Array Technology, PCR, Other Technologies. By product the noninvasive prenatal testing market is categorised as Consumables & Reagents, Instruments. By end-user the noninvasive prenatal testing market is categorised as Hospitals & Clinics, Diagnostic Laboratories. Geographically the research study provides data on North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions. This section provides the estimates of market by segment, thus providing valuable data to take strategic decisions.
The Report Segments Global Noninvasive Prenatal Testing Market -
By Gestation Period
- 0-12 Weeks
- 13-24 Weeks
- 25-36 Weeks
By Risk Type
- High & Average Risk
- Low Risk
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
- Array Technology
- Other Technologies
- Consumables & Reagents
- Hospitals & Clinics
- Diagnostic Laboratories
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Players Profiled In the Report:
Genesis Genetics (CooperSurgical, Inc.), Centogene N.V., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche Ltd (Ariosa Diagnostics), Progenity, Inc., Laboratory Corp. of America Holdings, Natera, Inc., Illumina, Inc. (Verinata Health, Inc.), MedGenome Labs Ltd., Myriad Women’s Health, Inc. (Myriad Genetics Inc/Counsyl, Inc.), QiagenQuest Diagnostics, Inc.
Download the FREE SAMPLE of Global Noninvasive Prenatal Testing Market Research Report
About Value Market Research -
Value Market Research was established with the vision to ease decision making and empower the strategists by providing them with holistic market information. Our analysts’ team is well equipped with all research tools and techniques and hold deep knowledge of the industry they are working for.
We ensure intellectual, precise and quality data is delivered to our client. We facilitate clients with syndicate research reports and customized research reports on 25+ industries with global as well as regional coverage.
Value Market Research
401/402, TFM, Nagras Road, Aundh, Pune-7.
Email: [email protected]